Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s stock price gapped down prior to trading on Wednesday . The stock had previously closed at $15.21, but opened at $14.21. Tonix Pharmaceuticals shares last traded at $16.27, with a volume of 515,692 shares trading hands.
Analysts Set New Price Targets
Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a report on Sunday, February 2nd. They set a "hold" rating for the company.
Check Out Our Latest Stock Analysis on TNXP
Tonix Pharmaceuticals Price Performance
The stock has a market cap of $23.17 million, a PE ratio of 0.00 and a beta of 2.07. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. The stock's 50-day moving average is $29.63 and its two-hundred day moving average is $26.35.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($23.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($203.00) by $180.00. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. The business had revenue of $2.82 million for the quarter, compared to analysts' expectations of $2.63 million. On average, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 earnings per share for the current year.
Institutional Trading of Tonix Pharmaceuticals
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC bought a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned approximately 0.12% of Tonix Pharmaceuticals as of its most recent filing with the SEC. 82.26% of the stock is owned by institutional investors.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Articles
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
